| Effect | Decrease |
| Values | ng/ml. Mean and SD. Placebo: before 85.9 ± 16.6, after 86.1 ± 17.7. Intervention: before 88.1 ± 17.7, after 77.6 ± 18.3. |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 48 |
| Sex | Both Genders |
In a randomized, double-blind, placebo-controlled trial, 48 participants with relapsing-remitting multiple sclerosis took 500 mg of coenzyme q10 or placebo daily for 12 weeks.
There was a greater reduction in TNF and IL-6 in the intervention group than the placebo group, the difference being statistically significant. Matrix metallopeptidase was also lowered significantly more, while TGF-β, IL-4, and disability scale results didn't show statistically significant differences.
